Strs Ohio Sells 12,500 Shares of Omnicell, Inc. $OMCL

Strs Ohio lowered its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 9.4% in the first quarter, HoldingsChannel reports. The fund owned 120,486 shares of the company’s stock after selling 12,500 shares during the period. Strs Ohio’s holdings in Omnicell were worth $4,022,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in OMCL. Raymond James Financial Inc. acquired a new stake in shares of Omnicell in the second quarter valued at approximately $26,000. Clearstead Advisors LLC boosted its holdings in Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after purchasing an additional 1,218 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in Omnicell during the fourth quarter worth $58,000. Parkside Financial Bank & Trust grew its position in Omnicell by 1,708.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after purchasing an additional 1,264 shares in the last quarter. Finally, First Horizon Corp grew its position in Omnicell by 54.6% in the fourth quarter. First Horizon Corp now owns 1,597 shares of the company’s stock valued at $72,000 after purchasing an additional 564 shares in the last quarter. 97.70% of the stock is owned by institutional investors.

Insider Transactions at Omnicell

In related news, EVP Corey J. Manley sold 5,025 shares of Omnicell stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. The trade was a 4.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the sale, the executive vice president directly owned 154,785 shares of the company’s stock, valued at $6,689,807.70. The trade was a 1.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.92% of the company’s stock.

Omnicell Stock Performance

Shares of OMCL traded down $0.66 during mid-day trading on Tuesday, reaching $44.58. The company’s stock had a trading volume of 41,273 shares, compared to its average volume of 635,248. The company has a current ratio of 1.50, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 1-year low of $26.84 and a 1-year high of $55.00. The business has a 50-day simple moving average of $41.92 and a two-hundred day simple moving average of $41.52. The stock has a market cap of $2.03 billion, a P/E ratio of 100.89, a PEG ratio of 1.11 and a beta of 0.96.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The business had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. During the same quarter in the prior year, the business earned $0.26 EPS. The firm’s revenue for the quarter was up 14.9% on a year-over-year basis. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, equities research analysts anticipate that Omnicell, Inc. will post 1.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Weiss Ratings upgraded Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Benchmark reaffirmed a “buy” rating on shares of Omnicell in a research report on Friday, March 13th. KeyCorp upped their target price on Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Finally, UBS Group set a $60.00 price target on Omnicell and gave the company a “buy” rating in a research note on Friday, March 13th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $59.86.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.